Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast for prevention of vancomycin-induced kidney injury
IRCT20200408046990N20Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF) comparing Montelukast with Placebo (2 arms). Primary endpoints: Incidence of vancomycin-induced renal failure, Serum creatinine and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
montelukast
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20200408046990N20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200408046990N20.